Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Brittany Pieniazek knew she had a chance of developing breast cancer. The Dyer resident’s mother and aunt had both been ...

BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding ...

DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical ...

We also are finalizing plans to begin the expansion portion of our trial, with an initial focus on patients with ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

non-small cell lung cancer and triple-negative breast cancer. The company also plans to initiate studies evaluating the therapy in combination with BioNTech’s antibody-drug conjugates.

non-small cell lung cancer and triple-negative breast cancer. BioNTech is also exploring combinations with antibody-drug ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...